Pediatric Psychopharmacology

When the first edition of Pediatric Psychopharmacology published in 2002, it filled a void in child and adolescent psychiatry and quickly establishing itself as the definitive text-reference in pediatric psychopharmacology. While numerous short, clinically focused paperbacks have been published since then, no competitors with the scholarly breadth, depth, and luster of this volume have emerged. In the second edition, Christopher Kratochvil, MD, a highly respected expert in pediatric psychopharmacology, joins the outstanding editorial team led by Dr. Martin and Dr. Scahill. In the new edition, the editors streamline the flow of information to reflect the growth in scientific data since the first edition appeared. The overall structure of the book remains the same, with major sections on underlying biology; somatic interventions; assessment and treatment; and special considerations.

Andrés Martin, MD, MPH is the Riva Ariella Ritvo Professor at the Yale Child Study Center. He serves as medical director of the Children's Psychiatric Inpatient Service (CIPS) at Yale-New Haven Children's Hospital, and as editor-in-chief of the flagship Journal of the American Academy of Child and Adolescent Psychiatry.
Lawrence Scahill, MSN, PhD is Professor of Nursing and Child Psychiatry at Yale University. He directs the Yale Research Unit on Pediatric Psychopharmacology focused on the development and testing of pharmacological treatments for children with serious psychiatric disorders.
Christopher J. Kratochvil, M.D. is the Assistant Vice Chancellor for Clinical Research at the University of Nebraska Medical Center. He serves as the Chief Medical Officer of UNeHealth. Additionally, he is a Professor of Psychiatry & Pediatrics, and Assistant Director of the Psychopharmacology Research Consortium.

Final Table of Contents:
Contributors xxiSECTION I BIOLOGICAL BASES OF PEDIATRIC PSYCHOPHARMACOLOGYI-A Developmental Principles of Neurobiology and Psychopharmacology 31. Overview of Brain Development 5Flora M. Vaccarino and James F. Leckman2. Synaptic Function and Biochemical Neuroanatomy 23Stephan Heckers, Christine Konradi, and George M. Anderson3. Developmental Principles of Pharmacokinetics 38Alexander A. Vinks, Philip D. Walson, and Shannon N. Saldaña4. Cytochrome P450-Mediated Interactions 50Jessica Oesterheld and Miia TurpeinenI-B Genetic Principles 655. Molecular Genetics 67Susan Goebel-Goody, Surojit Paul, and Paul J. Lombroso6. Pharmacogenetics 81George M. Anderson, Jeremy Veenstra-VanderWeele,Edwin H. Cook, and James T. McCrackenI-C Developmental Psychopathology 937. Neurobiology of Attention Regulation and its Disorders 95A.F.T. Arnsten and F.X. Castellanos8. Neurobiology of Early Life Stress: Evolving Concepts 112Joan Kaufman and Natalie Weder9. Neurobiology of Early-Onset Mood Disorders 124Frank P. MacMaster, David R. Rosenberg, and Joan Kaufman10. Neurobiology of Early-Onset Anxiety Disorders 139Kate B. Nooner, Amy K. Roy, and Daniel S. Pine11. Neurobiology of Obsessive-Compulsive Disorder 148Tanya K. Murphy, Kytja K.S. Voeller, and S. Evelyn Stewart12. Neurobiologic Substrates of Tic Disorders 171James F. Leckman, Michael H. Bloch, Michelle Hampson,and Robert A. King13. Neurobiology of Childhood Schizophrenia and Related Disorders 189Anand Mattai, Judith L. Rapoport, and Nitin Gogtay00-Martin_FM.indd xvii 10/4/2010 12:54:10 PMOUP UNCORRECTED PROOF - REVISES, 04/10/2010, GLYPHxviii CONTENTS14. Neurobiology of Autism Spectrum Disorders: Implications forImproving Pharmacotherapy 200Alexander Westphal and Kevin Pelphrey15. Neurobiology of Aggression 211Markus J.P. Kruesi, Sondra Keller, and Julie Ann Jensen16. Neurobiology of Eating Disorders 226Johannes Hebebrand, Kerstin Konrad, and Beate Herpertz-Dahlmann17. Neurobiology of Substance Abuse Disorders 237Kathryn J. Reissner and Peter W. Kalivas
SECTION II SOMATIC INTERVENTIONSII-A Psychotropic Agents 24918. Stimulants 251J. Daughton and Christopher Kratochvil19. á 2 -Adrenergic Agonists: Clonidine and Guanfacine 263Jeffrey H. Newcorn, Suzanne Clerkin, Kurt P. Schulz,and Jeffrey M. Halperin20. Antidepressants I: Selective Serotonin Reuptake Inhibitors 275Paul E. Croarkin, Graham J. Emslie, and Taryn L. Mayes21. Antidepressants II: Other Agents 296Emily Frosch22. Mood Stabilizers: Lithium, Anticonvulsants, and Others 297Robert A. Kowatch, Jeffrey R. Strawn, and Arman Danielyan23. Antipsychotic Agents: Traditional and Atypical 312Christoph U. Correll24. Anxiolytics and Sedative/Hypnotics: Benzodiazepines,Buspirone, and Others 338Shannon R. Barnett and Mark A. RiddleII-B Other Somatic Interventions 35125. Complementary and Alternative Medicine inPediatric Psychopharmacology 353Joseph M. Rey, Garry Walter, and Nerissa Soh26. Electroconvulsive Therapy, Transcranial Magnetic Stimulation,and Vagus Nerve Stimulation 363Garry Walter, Joseph M. Rey, Neera Ghaziuddin, and Colleen Loo
SECTION III ASSESSMENT AND TREATMENTIII-A General Principles 37727. Running a Pediatric Psychopharmacology Clinic: Practical Aspects 379Carlo G. Carandang, Christopher J. Kratochvil, Lawrence Scahill, andAndrés Martin28. Clinical Instruments and Scales in Pediatric Psychopharmacology 389Elizabeth Hurt, L. Eugene Arnold, and Michael G. Aman29. Combining Pharmacotherapy and Psychotherapy: An Evidence-basedApproach 407Christopher J. Kratochvil, Karen Wells, and John S. March00-Martin_FM.indd xviii 10/4/2010 12:54:10 PMOUP UNCORRECTED PROOF - REVISES, 04/10/2010, GLYPHCONTENTS xix30. Thinking About Prescribing: The Psychology ofPsychopharmacology 422Kyle D. Pruett, Shashank V. Joshi, and Andrés MartinIII-B Specifi c Disorders and Syndromes 43531. Assessment and Treatment of Attention Defi citHyperactivity Disorder 437Thomas Spencer, Joseph Biederman, and Timothy Wilens32. Assessment and Treatment of Child and AdolescentDepressive Disorders 453Boris Birmaher and David Brent33. Assessment and Treatment of Child and Adolescent Bipolar Disorder 466Jayasree J. Nandagopal and Melissa P. DelBello34. Assessment and Treatment of Child and AdolescentAnxiety Disorders 480John Walkup35. Assessment and Treatment of Obsessive Compulsive Disorder 496Gagan Joshi and Daniel A. Geller36. Assessment and Treatment of Tourette Syndrome andOther Tic Disorders 516Lawrence Scahill, Robert A. King, Paul Lombroso, Denis G. Sukhodolsky,and James F. Leckman37. Assessment and Treatment of Early-onset SchizophreniaSpectrum Disorders 531Linmarie Sikich and Terrence Carter Bethea38. Assessment and Treatment of Autistic and Other PervasiveDevelopmental Disorders 547Christopher J. McDougle and David J. Posey39. Assessment and Treatment of Post-traumatic Stress Disorder 561Craig L. Donnelly and Jennifer L. Mclaren40. Assessment and Treatment of Eating Disorders and Obesity 570Beate Herpertz-Dahlmann and Johannes HebebrandIII-C Special Clinical Populations 58541. Psychopharmacology and Substance Use Disorders 587Martin Gignac, James G. Waxmonsky, and Timothy Wilens42. Individuals with Intellectual Disability 600Michael G. Aman, Cristan A. Farmer, Ronald L. Lindsay,and L. Eugene Arnold43. Psychopharmacology in the Medically Ill Child or Adolescent 617Jonathan A. Slater, John Saroyan, and Nika Dyakina44. Psychopharmacology During Pregnancy: Infant Considerations 627C. Neill Epperson45. Psychopharmacological Treatment of Preschoolers 646Mary Margaret Gleason46. Insomnia in Children and Adolescents 657Judith A. Owens00-Martin_FM.indd xix 10/4/2010 12:54:10 PMOUP UNCORRECTED PROOF - REVISES, 04/10/2010, GLYPHxx CONTENTSIII-D Other Areas of Clinical Concern 66947. Aggression 671Bruce Meltzer, Martha Castro, and Jean A. Frazier48. Management of Elimination and Other Pelvic Disorders: Enuresis,Encopresis, and Psychopharmacological Effects on Sexual Function 682William Reiner
SECTION IV EPIDEMIOLOGICAL, RESEARCH, AND METHODOLOGICALCONSIDERATIONS49. Pediatric Psychopharmacoepidemiology: Who Is Prescribing?And For Whom, How, and Why? 697Peter S. Jensen50. Clinical Trials Methodology and Design 711Benedetto Vitiello and Lawrence Scahill51. Regulatory Issues 725Thomas P. Laughren and Mark A. Ritter52. Ethical Issues in Pediatric Psychopharmacology 738Mary Lynn Dell, Brigette S. Vaughan, and Christopher Kratochvil53. Confl icts of Interest 752Garry Walter, Joseph M. Rey, Christopher R. Thomas, and Andrés Martin54. International Perspectives on Pediatric Medication forEmotional and Behavioral Disorders 763Daniel J. Safer and Julie M. Zito
Appendix 775Disclosures of Financial Interest 785Index 791